Galit Weinstein, Green Manfred S, Lital Keinan-Boker
Israel Center for Disease Control, Ministry of Health, Israel.
Maturitas. 2007 Jun 20;57(2):109-19. doi: 10.1016/j.maturitas.2007.01.010. Epub 2007 Mar 1.
The efficacy of population screening mammography for the age group of 50-74 years has been demonstrated. However, only limited data are available regarding women aged 75 and over, and recommendations for breast cancer screening in this age group vary in different countries. The aim of the current study is to review the evidence of the efficacy of breast cancer screening in women over the age of 74 years.
Studies published in English were retrieved by systematically searching MEDLINE (for papers published until August 2006), and by manually examining the references of the original articles and reviews retrieved. All studies that dealt with screening mammography over age 74 years were included. The studies were reviewed according to their outcomes and study design, focusing on breast cancer mortality and stage of breast cancer at diagnosis.
Three studies focused on the relationship between breast cancer screening and mortality; in the 75-84 years age group, the risk of disease-specific mortality was approximately two-fold higher among women who did not perform screening mammography compared to women who did. Another four studies showed that women who underwent screening mammography had significantly smaller tumors and earlier disease stage at diagnosis.
Regular mammography screening in older women may be associated with an earlier-stage disease and lower breast cancer mortality. These data support the use of screening mammography above age 75 years based on individual evaluations, rather than setting an upper age limit for breast cancer screening.
已证实针对50 - 74岁年龄组的群体乳腺钼靶筛查的有效性。然而,关于75岁及以上女性的数据有限,且不同国家对该年龄组乳腺癌筛查的建议各不相同。本研究的目的是回顾74岁以上女性乳腺癌筛查有效性的证据。
通过系统检索MEDLINE(检索截至2006年8月发表的论文)以及人工查阅检索到的原始文章和综述的参考文献,获取以英文发表的研究。纳入所有涉及74岁以上乳腺钼靶筛查的研究。根据研究结果和研究设计对这些研究进行综述,重点关注乳腺癌死亡率和诊断时乳腺癌的分期。
三项研究聚焦于乳腺癌筛查与死亡率之间的关系;在75 - 84岁年龄组中,未进行乳腺钼靶筛查的女性的疾病特异性死亡风险比进行筛查的女性高出约两倍。另外四项研究表明,接受乳腺钼靶筛查的女性在诊断时肿瘤明显更小且疾病分期更早。
老年女性定期进行乳腺钼靶筛查可能与疾病早期阶段和较低的乳腺癌死亡率相关。这些数据支持基于个体评估对75岁以上女性使用乳腺钼靶筛查,而不是为乳腺癌筛查设定年龄上限。